Medco may need buyouts to maintain sales; GW Pharma wins Danish OK for Sativex;

@FiercePharma: Dendreon to test Provenge in early-stage cancer. Report | Follow @FiercePharma

> Medco Health Solutions, the pharmacy benefits manager that lost $3.5 billion in contracts since March, may seek acquisitions to make up for lost revenue if its biggest remaining client fails to re-sign this year. News

> GW Pharmaceuticals' cannabis-based drug Sativex has been approved in Denmark for the treatment of spasticity due to multiple sclerosis. Story

> Biogen Idec has announced that the European Commission has granted approval to its multiple sclerosis treatment device, the Avonex Pen. Report

> Two new biomarkers for prostate cancer may improve faulty PSA tests. News 

> At least 30 percent of employers are likely to stop offering health insurance once provisions of the U.S. health care reform law kick in in 2014, according to a study by consultant McKinsey. Article

> Proteomics brings saliva biomarkers within spitting distance. Item 

> India's Department of Pharmaceuticals is proposing an updated Uniform Code of Marketing Practice for drugmakers that would tighten rules on doling out samples and encounters between docs and reps. Item

> Biomarkers identified for Avastin resistance in cancer patients. Piece 

> Lawyers for the Obama administration are scheduled to ask a third federal appeals court to uphold a 2010 healthcare law in what may be the final legal battle over the statute before it reaches the U.S. Supreme Court. Story

> Officials say they are "concerned" at new findings which show that more than 1 million Australians--9.7 percent of the population--cannot afford to buy medicines which they have been prescribed. News

> Drugstore chain Brazil Pharma could raise as much as 520 million reais ($329 million) in an initial public offering set to price later this month. Report

Biotech News

@FierceBiotech: Cancer pacts sizzle as developers start to team early on combos. Story| Follow @FierceBiotech

@JohnCFierce: Bloomberg: Last 12 months we've seen 226 announced U.S. pharma acquisitions; average disclosed deal size of $204.7 million; 40 percent average premium. | Follow @JohnCFierce

> In fresh blow, Intercell and Merck dump Ph2/3 vaccine study. Report

> Biogen Idec makes a shopping list for buyouts and licensing deals. Item

Drug Delivery News

> Visions of self-assembling nanomedicine dance in researchers' heads. Report

> Brain tumor starved of iron, making chemo more effective. News 

> Cholera molecule helps cocaine addicts kick the habit. Story 

> MicroDose proving itself to military as inhaled nerve-agent treatment. Article 

> 'Smart bombs' deliver kidney cancer medication. Item 

>  Drug-delivery device design impacts patient compliance. Report 

Medical Device News

> Crux raises $12M in investment round. News

> FDA panel to review Edwards SAPIEN valve next month. Article 

> Roche, Merck to collaborate on cancer diagnostics. Story 

> Ubl, MacMillan present 'Competitiveness Agenda' for med tech. Item 

> Appeals court finds for Boston Sci in stent case. Article 

> PolyRemedy nabs $20M in Series C. Item

And Finally... Former U.S. President Bill Clinton said the United States could save more than $1 trillion a year by adopting any other advanced nation's healthcare system. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.